IDENTIFYSENSORS ADDS FOUR REGULATORY AND QUALITY EXPERTS TO MOVE NEW TECHNOLOGY TO COMMERCIALIZATION
Retrieved on:
Monday, March 27, 2023
Aureus, Tuberculosis, HIV, Lyme, Escherichia coli, ISO, Infection, COVID-19, MRSA, Risk management, Hoda Kotb, Sale, Hepatitis C, RSV, Dicarboxylic acid, Hosey, Michel Amacker, Supply chain, Methicillin-resistant Staphylococcus aureus, Engineering, Vertically transmitted infection, Salmonella, Supply, Adenoviridae, Fluid mechanics, FDA, Rotavirus, Medical device, Management, Video game, Vaccine, Legionella, Coronavirus, Quality, Norovirus
CLEVELAND, March 27, 2023 /PRNewswire/ -- IdentifySensors® Biologics, a leading developer of digital diagnostic technologies, has named four new industry specialists in regulatory, quality and supply chain to oversee good manufacturing and FDA submissions for the company's Check4® digital diagnostics platform product pipeline.
Key Points:
- "I am very excited about this new quality and regulatory team," said IdentifySensors CEO Greg Hummer, M.D.
- "This is one of the most proficient and accomplished groups in the diagnostics industry, as we move this breakthrough technology through the regulatory process and on to large-scale manufacturing.
- The new team will report to Ghazi Kashmolah, IdentifySensors' executive vice president of regulatory affairs and chief quality officer.
- With extensive experience managing in vitro diagnostic devices, design control processes, ISO 13485 compliance and risk management, Amacker will serve as director of Quality.